MilliporeSigma

[Lamotrigine in treatment of women with epilepsy].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2011-01-01)
P N Vlasov, D V Dranko, O V Agranovich
ABSTRACT

The paper presents the review of literature on the age aspect of using lamotrigine in pubertal period, in women of reproductive age, during pregnancy and lactation and in climacteric period. Special attention is drawn to the low teratogenic potential of this drug used as a monotherapy. It has been concluded that lamotrigine is expedient to be used in treatment of partial and generalized epilepsy in women.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Lamotrigine, ≥98%, powder
Lamotrigine for system suitability, European Pharmacopoeia (EP) Reference Standard
USP
Lamotrigine, United States Pharmacopeia (USP) Reference Standard
Lamotrigine for peak identification, European Pharmacopoeia (EP) Reference Standard
Lamotrigine, European Pharmacopoeia (EP) Reference Standard
Supelco
Lamotrigine, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Lamotrigine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®